| Revision as of 17:51, 8 December 2017 editRhode Island Red (talk | contribs)Extended confirmed users14,311 edits Reverted to revision 813334784 by KolbertBot (talk): Not WP:MEDRS; and announcements of tenntative events are not encylopedia worthy. (TW)← Previous edit | Revision as of 17:55, 8 December 2017 edit undoRhode Island Red (talk | contribs)Extended confirmed users14,311 edits →Development: press releases of unrefereed studies are not encyclopedic or WP:MEDRS; same with planned studiesNext edit → | ||
| Line 8: | Line 8: | ||
| == Development == | == Development == | ||
| Activity has been seen in a phase II trial for metastatic ].<ref name=TNBC2015></ref> It was included in the ] adaptive clinical trial for breast cancer and has 'graduated' to the later stage trials.<ref name=Kuznar/> | |||
| Immunomedics announced in late 2016 that they plan to submit a ] to the FDA within the next year.<ref>http://adisinsight.springer.com/drugs/800037529</ref> | Immunomedics announced in late 2016 that they plan to submit a ] to the FDA within the next year.<ref>http://adisinsight.springer.com/drugs/800037529</ref> | ||
| Under a ] agreement, Immunomedics is conducting a ] in patients with triple-negative breast cancer.<ref>https://clinicaltrials.gov/ct2/show/NCT02574455</ref> | |||
| ==References== | ==References== | ||
Revision as of 17:55, 8 December 2017
 | This article needs more reliable medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Sacituzumab govitecan" – news · newspapers · books · scholar · JSTOR (January 2017) |  |
Sacituzumab govitecan (IMMU-132 or hRS7-SN-38) is an antibody-drug conjugate being investigated as a treatment for cancers such as pancreatic cancers, small-cell lung cancer (SCLC) and triple-negative breast cancer. It is being developed by Immunomedics, and in 2017, was licensed to Seattle Genetics.
The FDA granted breakthrough therapy status, an expedited investigational drug development pathway, in February 2016. Fast track designation was received in 2013 for treatment of non-small cell lung cancer, small cell lung cancer, and metastatic triple-negative breast cancer. Orphan drug status was granted for small cell lung cancer and pancreatic cancer.
Mechanism
It is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 6.7 molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.
Development
Immunomedics announced in late 2016 that they plan to submit a Biological License Application to the FDA within the next year.
References
- FDA Fast Track for TNBC
- New Therapy Shows Early Promise, Continues to Progress in Triple-Negative Breast Cancer. Feb 2016
- http://adisinsight.springer.com/drugs/800037529
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. 2015
- Novel Agents are Targeting Drivers of TNBC. 2016
- http://adisinsight.springer.com/drugs/800037529
External links
- IMMU-132 (Sacituzumab Govitecan) Mentions FDA Orphan drug status, mechanism of action, and clinical trials
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |